Login / Signup

Phosphoethanolamine Transferases as Drug Discovery Targets for Therapeutic Treatment of Multi-Drug Resistant Pathogenic Gram-Negative Bacteria.

Van C ThaiKeith A StubbsMitali Sarkar-TysonCharlene M Kahler
Published in: Antibiotics (Basel, Switzerland) (2023)
Antibiotic resistance caused by multidrug-resistant (MDR) bacteria is a major challenge to global public health. Polymyxins are increasingly being used as last-in-line antibiotics to treat MDR Gram-negative bacterial infections, but resistance development renders them ineffective for empirical therapy. The main mechanism that bacteria use to defend against polymyxins is to modify the lipid A headgroups of the outer membrane by adding phosphoethanolamine (PEA) moieties. In addition to lipid A modifying PEA transferases, Gram-negative bacteria possess PEA transferases that decorate proteins and glycans. This review provides a comprehensive overview of the function, structure, and mechanism of action of PEA transferases identified in pathogenic Gram-negative bacteria. It also summarizes the current drug development progress targeting this enzyme family, which could reverse antibiotic resistance to polymyxins to restore their utility in empiric therapy.
Keyphrases
  • multidrug resistant
  • drug resistant
  • gram negative
  • acinetobacter baumannii
  • drug discovery
  • public health
  • klebsiella pneumoniae
  • fatty acid
  • cancer therapy
  • stem cells
  • replacement therapy
  • bone marrow
  • global health